OVARIAN UNDIFFERENTIATED CARCINOMA
Clinical trials for OVARIAN UNDIFFERENTIATED CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN UNDIFFERENTIATED CARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN UNDIFFERENTIATED CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to extend life in recurrent ovarian cancer
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with recurrent ovarian, peritoneal, or fallopian tube cancer live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus bevacizumab, …
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:41 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo shows promise
Disease control OngoingThis study tests whether adding a drug called AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has returned and is resistant to platinum-based treatments. About 124 women will be randomly assigned to receive either…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:39 UTC
-
Weekly chemo may improve outcomes for advanced ovarian cancer patients
Disease control OngoingThis study tested two different ways of giving the chemotherapy drug paclitaxel (either once every three weeks or once a week) along with carboplatin, with or without the targeted drug bevacizumab, in 692 people with advanced ovarian, peritoneal, or fallopian tube cancer. The goa…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo could offer alternative to chemo for recurrent ovarian cancer
Disease control OngoingThis phase 3 study tested whether the targeted drugs olaparib (alone or combined with cediranib) work better than standard platinum-based chemotherapy for women with ovarian, fallopian tube, or primary peritoneal cancer that came back after initial treatment. About 579 women with…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Measles virus hijacks stem cells to attack returning ovarian cancer
Disease control OngoingThis study tests a new way to treat ovarian cancer that has come back after standard chemotherapy. Doctors take stem cells from fat tissue, infect them with a specially modified measles virus, and inject them into the belly. The stem cells carry the virus directly to cancer cells…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New hope for ovarian cancer: drug combo targets resistant tumors
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The goal is to find the safest dose and see if the combo can shrink tumors or slow their gr…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New drug duo shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study looked at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back or grew during platinum-based chemo. About 582 women took pa…
Matched conditions: OVARIAN UNDIFFERENTIATED CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC